All Stories

  1. Recognizing Coagulation Disorders in Sepsis in the Emergency Room: A Narrative Review
  2. Damage-associated Molecular Patterns, Immunothrombosis, and Intravascular Inflammation in Sepsis: A Narrative Integrative Review
  3. Sepsis and heatstroke: overlapping and distinct mechanisms of systemic inflammation
  4. TIGRIS and EUPHRATES eventually join and provide new evidence: a narrative review of the polymyxin B hemoperfusion
  5. Heat stress-induced mitochondrial damage and its impact on leukocyte function
  6. Endotoxin Activity Assay-Guided Patient Selection for Polymyxin B Hemoperfusion: Lessons from the TIGRIS Trial and Future Directions
  7. Factors influencing antithrombin activity following supplementation in sepsis-associated disseminated intravascular coagulation
  8. Re-evaluating the impact of ventilator-associated events on mortality in critically ill patients: insights from advanced causal modeling
  9. Granulomonocytapheresis for chronic inflammatory diseases and sepsis
  10. Proteomics-based monitoring of heatstroke recovery identifies molecular signatures of organ stress
  11. Introducing the New Definition and Diagnostic Criteria of Disseminated Intravascular Coagulation Released by the International Society on Thrombosis and Haemostasis in 2025
  12. Mortality, diagnosis, and etiology of disseminated intravascular coagulation—a systematic review and meta-analysis: communication from the ISTH SSC subcommittee on disseminated intravascular coagulation
  13. Evolution of Clinical Trials in Anticoagulation for Sepsis: Bridging Past to Future
  14. Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation
  15. Disseminated intravascular coagulation and cirrhotic coagulopathy: overlap and differences. The current state of knowledge. Communication from the SSC of the ISTH
  16. The role of viscoelastic tests in the diagnosis of sepsis-induced coagulopathy (SIC)
  17. Mitochondrial dysfunction is a major cause of thromboinflammation and inflammatory cell death in critical illnesses
  18. Impact of hyper- and hypothermia on cellular and whole-body physiology
  19. History of Disseminated Intravascular Coagulation (DIC) Research and My Personal Research History
  20. Is Antithrombin Supplementation Effective in Suppressing ECMO Circuit Thrombosis in Sepsis?
  21. Molecular Mechanisms of Heatstroke: Pathophysiology and Cell Death Pathways
  22. Diagnosis and Management of Heat-related Illness: Clinical and Molecular Perspectives
  23. Endotoxin Hemoperfusion as an Adjuvant Therapy for Sepsis: Lessons from the TIGRIS Trial
  24. Reply to the comments on “Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?” from Wada et al.
  25. Autophagy and autophagic cell death in sepsis: friend or foe?
  26. Sepsis-induced coagulopathy (SIC) in the management of sepsis
  27. Determining prognostic indicator for anticoagulant therapy in sepsis-induced disseminated intravascular coagulation
  28. Deranged Balance of Hemostasis and Fibrinolysis in Disseminated Intravascular Coagulation: Assessment and Relevance in Different Clinical Settings
  29. Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?
  30. The role of thromboinflammation in acute kidney injury among patients with septic coagulopathy
  31. Heparins May Not Be the Optimal Anticoagulants for Sepsis and Sepsis-Associated Disseminated Intravascular Coagulation
  32. Proposal and Validation of a Clinically Relevant Modification of the Japanese Association for Acute Medicine Disseminated Intravascular Coagulation Diagnostic Criteria for Sepsis
  33. Managing sepsis and septic shock in an endothelial glycocalyx-friendly way: from the viewpoint of surviving sepsis campaign guidelines
  34. Designing Future Clinical Trials for Sepsis-associated Disseminated Intravascular Coagulation
  35. Endothelial Glycocalyx Protection in Sepsis
  36. Fibrinolytic Changes in Critical Illnesses: Is Fibrinolysis Shutdown a Specific Concept?
  37. Mitochondrial Damage in Sepsis
  38. Organ Dysfunction in Sepsis-associated Intravascular Coagulation
  39. The Detection of Neutrophil Activation by Automated Blood Cell Counter in Sepsis
  40. The Effect of Antiplatelet Therapy on COVID-19
  41. Why is DIC a Rare Diagnosis in the 21<sup>st</sup> Century?
  42. Risk stratification utilizing sequential organ failure assessment (SOFA) score, antithrombin activity, and demographic data in sepsis-associated disseminated intravascular coagulation (DIC)
  43. Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis
  44. Mechanisms and management of the coagulopathy of trauma and sepsis: trauma-induced coagulopathy, sepsis-induced coagulopathy, and disseminated intravascular coagulation
  45. The antithrombin activity recovery after substitution therapy is associated with improved 28-day mortality in patients with sepsis-associated disseminated intravascular coagulation
  46. Persistent and Late-Onset Disseminated Intravascular Coagulation Are Closely Related to Poor Prognosis in Patients with Sepsis
  47. What Role Does Microthrombosis Play in Long COVID?
  48. A commentary on “Thromboinflammation in long COVID – the elusive key to post-infection sequelae?”
  49. Thromboinflammation in acute injury: infections, heatstroke, and trauma
  50. Super Formula for Diagnosing Disseminated Intravascular Coagulation Using Soluble C-Type Lectin-like Receptor 2
  51. What’s fishy about protamine? Clinical use, adverse reactions, and potential alternatives
  52. “Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis on sepsis-induced coagulopathy in the management of sepsis”: reply
  53. The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation
  54. Thrombotic Mechanism Involving Platelet Activation, Hypercoagulability and Hypofibrinolysis in Coronavirus Disease 2019
  55. Communication from the Scientific Standardization Committees of the International Society on Thrombosis and Haemostasis on vascular endothelium-related biomarkers in disseminated intravascular coagulation
  56. Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on sepsis-induced coagulopathy in the management of sepsis
  57. Designing the Diagnostic Criteria for Disseminated Intravascular Coagulation (DIC)
  58. Disseminated Intravascular Coagulation: The Past, Present, and Future Considerations
  59. Intracellular communication and immunothrombosis in sepsis
  60. Morphological Changes in Blood Cells in a Rat Model of Heatstroke: A Pilot Study
  61. ISTH guidelines for antithrombotic treatment in COVID ‐19
  62. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination
  63. Elevated Plasma Soluble C-Type Lectin-like Receptor 2 Is Associated with the Worsening of Coronavirus Disease 2019
  64. Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management
  65. Nevertheless, the importance of coagulation abnormalities should be emphasized in international sepsis guidelines
  66. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia
  67. Roles of Coagulation Abnormalities and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment
  68. Viral-Induced Inflammatory Coagulation Disorders: Preparing for Another Epidemic
  69. COVID‐19: Thrombosis, thromboinflammation, and anticoagulation considerations
  70. Soluble C-Type Lectin-Like Receptor 2 Is a Biomarker for Disseminated Intravascular Coagulation
  71. Endothelial Injury in COVID-19 and Acute Infections
  72. Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy
  73. Diagnosis of Sepsis by AI-Aided Proteomics Using 2D Electrophoresis Images of Patient Serum Incorporating Transfer Learning for Deep Neural Networks
  74. Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?
  75. Proposal of the Definition for COVID-19-Associated Coagulopathy
  76. Recent advances in the research and management of sepsis-associated DIC
  77. Editorial commentary: Vascular injury in acute infections and COVID-19: everything old is new again
  78. Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis
  79. COVID‐19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry—Communication from the ISTH SSC for Women’s Health
  80. The coagulopathy, endotheliopathy, and vasculitis of COVID-19
  81. ISTH DIC subcommittee communication on anticoagulation in COVID‐19
  82. Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis
  83. Coagulopathy in COVID‐19
  84. The unique characteristics of COVID-19 coagulopathy
  85. RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis‐induced coagulopathy than fibrin‐related markers: Response to the Letter‐to‐the‐Editor by Dr Wada
  86. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis‐associated coagulopathy: A systematic review and meta‐analysis
  87. Diagnosis and management of sepsis‐induced coagulopathy and disseminated intravascular coagulation
  88. The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases
  89. DIC in obstetrics: Diagnostic score, highlights in management, and international registry‐communication from the DIC and Women's Health SSCs of the International Society of Thrombosis and Haemostasis
  90. Proposal of a two‐step process for the diagnosis of sepsis‐induced disseminated intravascular coagulation
  91. Current status of venous thromboembolism development during the perioperative period for colorectal cancer, its prevention with enoxaparin, and monitoring methods
  92. Sepsis-associated disseminated intravascular coagulation and its differential diagnoses
  93. The wind changed direction and the big river still flows: from EUPHRATES to TIGRIS
  94. Diagnosis of sepsis‐induced disseminated intravascular coagulation and coagulopathy
  95. Derangement of the endothelial glycocalyx in sepsis
  96. Differential diagnoses for sepsis‐induced disseminated intravascular coagulation: communication from the SSC of the ISTH
  97. Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation
  98. Oh, how hard it is to open the gate for sepsis trials: lessons from SCARLET
  99. Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis
  100. Role of extracellular vesicles in the development of sepsis-induced coagulopathy
  101. Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation
  102. Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality
  103. Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin
  104. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis
  105. Modified DIC diagnostic criteria
  106. Efficacy and Bleeding Risk of Antithrombin Supplementation in Patients With Septic Disseminated Intravascular Coagulation: A Third Survey
  107. Physiological Levels of Pentraxin 3 and Albumin Attenuate Vascular Endothelial Cell Damage Induced by Histone H3In Vitro
  108. Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect
  109. Antithrombin or thrombomodulin administration in severe pneumonia patients with sepsis and disseminated intravascular coagulation: comment on two papers
  110. Combination of antithrombin and recombinant thrombomodulin modulates neutrophil cell-death and decreases circulating DAMPs levels in endotoxemic rats
  111. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan
  112. Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus
  113. Neutrophil extracellular traps, damage-associated molecular patterns, and cell death during sepsis
  114. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation
  115. Recombinant thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model